South Korea approves first biosimilar Remsima from Celltrion to compete with Remicade

South Korea has granted the first approval worldwide to a biosimilar version of Johnson & Remicade (infliximab) from Johnson & Johnson/Merck Inc. ).The regulatory clearance is for Remsima (CT-P13) from Celltrion and is also the first to be given anywhere to a biosimilar monoclonal antibody.Remsima may also be launched by the end of the year in a number of Asian and South American markets,